Taysha Gene Therapies, Inc. (TSHA) 10-Year Financial Performance & Capital Metrics

TSHA • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.Show more

Revenue $8M -46.1%
EBITDA -$90M -26.9%
Net Income -$89M +20.0%
EPS (Diluted) -0.36 +62.8%
Gross Margin 100%
EBITDA Margin -1082.61% -135.4%
Operating Margin -1097.55% -134.1%
Net Margin -1071.62% -48.4%
ROE -121.94% +58.5%
ROIC -
Debt/Equity 0.88 +8.3%
Interest Coverage -896.66 -6086.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 91 (top 9%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Expensive at 17.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-36.36%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-338.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM-948.52%

ROCE

10Y Avg-73.98%

5Y Avg-73.98%

3Y Avg-84.01%

Latest-67.72%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	2.5M	15.45M	8.33M
Revenue Growth %	-	-	-	-	5.18%	-0.46%
Cost of Goods Sold+	0	9K	0	2.49M	0	0
COGS % of Revenue	-	-	-	0.99%	-	-
Gross Profit+	0	-9K	0	15K	15.45M	8.33M
Gross Margin %	-	-	-	0.01%	1%	1%
Gross Profit Growth %	-	-	1%	-	1029.14%	-0.46%
Operating Expenses+	1.11M	42.99M	173.27M	126.04M	87.89M	99.79M
OpEx % of Revenue	-	-	-	50.38%	5.69%	11.98%
Selling, General & Admin	128K	11.1M	41.32M	34.87M	30.05M	28.95M
SG&A % of Revenue	-	-	-	13.94%	1.94%	3.47%
Research & Development	987K	31.89M	131.94M	91.17M	56.78M	66M
R&D % of Revenue	-	-	-	36.44%	3.67%	7.92%
Other Operating Expenses	0	0	0	0	1.06M	4.84M
Operating Income+	-1.11M	-43M	-173.27M	-126.03M	-72.44M	-91.46M
Operating Margin %	-	-	-	-50.37%	-4.69%	-10.98%
Operating Income Growth %	-	-37.57%	-3.03%	0.27%	0.43%	-0.26%
EBITDA+	3.35M	-42.99M	-172.78M	-123.54M	-71.07M	-90.21M
EBITDA Margin %	-	-	-	-49.38%	-4.6%	-10.83%
EBITDA Growth %	-	-13.85%	-3.02%	0.28%	0.42%	-0.27%
D&A (Non-Cash Add-back)	4.46M	9K	492K	2.49M	1.37M	1.25M
EBIT	-4.46M	-59.98M	-173.09M	-162.22M	-106.57M	-89.2M
Net Interest Income+	0	21K	-1.26M	-3.55M	-1.43M	6.84M
Interest Income	0	49K	172K	249K	3.57M	6.94M
Interest Expense	0	28K	1.43M	3.8M	5M	102K
Other Income/Expense	0	-17.01M	-1.26M	-39.99M	-39.13M	2.16M
Pretax Income+	-1.11M	-60.01M	-174.52M	-166.01M	-111.57M	-89.3M
Pretax Margin %	-	-	-	-66.35%	-7.22%	-10.72%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	0.72%	1%	1%	1%	1%
Net Income+	-1.11M	-43M	-174.52M	-166.01M	-111.57M	-89.3M
Net Margin %	-	-	-	-66.35%	-7.22%	-10.72%
Net Income Growth %	-	-37.57%	-3.06%	0.05%	0.33%	0.2%
Net Income (Continuing)	-1.11M	-60.01M	-174.52M	-166.01M	-111.57M	-89.3M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.03	-3.40	-4.64	-3.78	-0.96	-0.36
EPS Growth %	-	-111.86%	-0.36%	0.19%	0.75%	0.63%
EPS (Basic)	-0.03	-3.40	-4.64	-3.78	-0.96	-0.36
Diluted Shares Outstanding	36.99M	17.67M	37.65M	43.95M	116.12M	250.13M
Basic Shares Outstanding	36.99M	17.67M	37.65M	43.95M	116.12M	250.13M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15K	257.88M	159.6M	96.42M	149.87M	142.13M
Cash & Short-Term Investments	0	251.25M	149.1M	87.88M	143.94M	139.04M
Cash Only	0	251.25M	149.1M	87.88M	143.94M	139.04M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	15K	331K	6.63M	1.19M	3.42M	892K
Total Non-Current Assets+	15K	1M	54.35M	29.86M	22.86M	18.23M
Property, Plant & Equipment	0	287K	50.61M	25.91M	20.41M	15.87M
Fixed Asset Turnover	-	-	-	0.10x	0.76x	0.53x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	2.64M	0	0	0
Other Non-Current Assets	15K	715K	1.11M	3.95M	2.46M	2.37M
Total Assets+	15K	258.88M	213.96M	126.28M	172.73M	160.36M
Asset Turnover	-	-	-	0.02x	0.09x	0.05x
Asset Growth %	-	17257.73%	-0.17%	-0.41%	0.37%	-0.07%
Total Current Liabilities+	150K	7.13M	51.75M	62.79M	36.76M	26.23M
Accounts Payable	0	1.99M	21.76M	10.95M	6.37M	3.59M
Days Payables Outstanding	-	80.87K	-	1.61K	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	1000K	1000K	1000K
Other Current Liabilities	21K	1.86M	4.13M	4.63M	4.99M	6.43M
Current Ratio	0.10x	36.17x	3.08x	1.54x	4.08x	5.42x
Quick Ratio	0.10x	36.17x	3.08x	1.54x	4.08x	5.42x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	450K	66.83M	62.54M	61.04M	62.61M
Long-Term Debt	0	0	37.19M	37.97M	40.51M	43.94M
Capital Lease Obligations	0	0	25.9M	20.44M	18.95M	17.36M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	450K	3.73M	4.13M	1.58M	1.31M
Total Liabilities	150K	7.58M	118.57M	125.33M	97.79M	88.84M
Total Debt+	0	0	63.09M	59.93M	61.11M	63.18M
Net Debt	0	-251.25M	-86.01M	-27.95M	-82.83M	-75.86M
Debt / Equity	-	-	0.66x	63.15x	0.82x	0.88x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-1535.79x	-121.34x	-33.18x	-14.49x	-896.66x
Total Equity+	-135K	251.3M	95.38M	949K	74.94M	71.53M
Equity Growth %	-	1862.5%	-0.62%	-0.99%	77.96%	-0.05%
Book Value per Share	-0.00	14.23	2.53	0.02	0.65	0.29
Total Shareholders' Equity	-135K	251.3M	95.38M	949K	74.94M	71.53M
Common Stock	0	0	0	1K	2K	2K
Retained Earnings	-1.11M	-61.13M	-235.65M	-401.44M	-513.01M	-602.3M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	-4.03M
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	135K	-30.73M	-117.04M	-88.39M	-73.02M	-81.22M
Operating CF Margin %	-	-	-	-35.33%	-4.73%	-9.75%
Operating CF Growth %	-	-228.62%	-2.81%	0.24%	0.17%	-0.11%
Net Income	-1.11M	-60.01M	-174.52M	-166.01M	-111.57M	-89.3M
Depreciation & Amortization	0	9K	492K	1.17M	1.37M	1.25M
Stock-Based Compensation	0	3.35M	18.18M	18.04M	7.91M	13.1M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	710K	26.03M	10.14M	39.89M	47.28M	6.19M
Working Capital Changes	540K	-111K	28.67M	18.52M	-18.01M	-12.47M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	1.96M	14.49M	-7.8M	-2.29M	-2.92M
Cash from Investing+	0	-9.08M	-21.55M	-24.93M	-7.35M	-363K
Capital Expenditures	0	-82K	-21.55M	-24.87M	-3.87M	-374K
CapEx % of Revenue	-	-	-	9.94%	0.25%	0.04%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	-9M	0	-61K	-3.48M	11K
Cash from Financing+	0	291.06M	39.08M	52.1M	136.39M	76.68M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	-514K	-1.15M	-947K	-96K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	135K	-39.81M	-138.6M	-113.26M	-80.39M	-81.6M
FCF Margin %	-	-	-	-45.27%	-5.2%	-9.79%
FCF Growth %	-	-295.9%	-2.48%	0.18%	0.29%	-0.02%
FCF per Share	0.00	-2.25	-3.68	-2.58	-0.69	-0.33
FCF Conversion (FCF/Net Income)	-0.12x	0.71x	0.67x	0.53x	0.65x	0.91x
Interest Paid	0	28K	641K	2.77M	4.95M	5.28M
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-34.24%	-100.68%	-344.67%	-294.04%	-121.94%
Return on Invested Capital (ROIC)	-	-	-2758.74%	-	-	-
Gross Margin	-	-	-	0.6%	100%	100%
Net Margin	-	-	-	-6635.25%	-722.06%	-1071.62%
Debt / Equity	-	-	0.66x	63.15x	0.82x	0.88x
Interest Coverage	-	-1535.79x	-121.34x	-33.18x	-14.49x	-896.66x
FCF Conversion	-0.12x	0.71x	0.67x	0.53x	0.65x	0.91x
Revenue Growth	-	-	-	-	517.55%	-46.07%

Frequently Asked Questions

Growth & Financials

Taysha Gene Therapies, Inc. (TSHA) reported $6.3M in revenue for fiscal year 2024.

Taysha Gene Therapies, Inc. (TSHA) saw revenue decline by 46.1% over the past year.

Taysha Gene Therapies, Inc. (TSHA) reported a net loss of $99.9M for fiscal year 2024.

Dividend & Returns

Taysha Gene Therapies, Inc. (TSHA) has a return on equity (ROE) of -121.9%. Negative ROE indicates the company is unprofitable.

Taysha Gene Therapies, Inc. (TSHA) had negative free cash flow of $85.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener